Current knowledge about pathogenesis and treatment of arterial hypertension in rheumatoid arthritis


Cite item

Full Text

Abstract

Rheumatoid arthritis (RA) is a chronic autoimmune disease with a proved high risk of cardiovascular diseases (CVD). An increase of this risk is mainly due to accumulation of conventional factors of CVD development (arterial hypertension - AH), dislipidemia, et cet). Causes of high prevalence of AH in RA, the role of chronic inflammation, effects of antirheumatic drugs with potentially hypertensive effects are outlined and recommendations on AH prevention and treatment in RA patients are given.

About the authors

Diana Sergeevna Novikova

Email: diananovikova75@yandex.ru

Tat'yana Valentinovna Popkova

Email: popkovatv@mail.ru

Evgeniy L'vovich Nasonov

Email: sokrat@irramn.ru

D S Novikova

Research Institute of Rheumatology of AMS, Moscow

Research Institute of Rheumatology of AMS, Moscow

T V Popkova

Research Institute of Rheumatology of AMS, Moscow

Research Institute of Rheumatology of AMS, Moscow

E L Nasonov

Research Institute of Rheumatology of AMS, Moscow

Research Institute of Rheumatology of AMS, Moscow

References

  1. Насонов Е. Л., Насонова В. А. (ред.). Ревматология: Нац. руководство. М.: Гэотар-Медиа; 2008.
  2. Meune С., Touze E., Trinqurte L. et al. Trends in cardiovascular mortality in patients with rheumatoid arthritis over 50 years: a systematic review and meta-analisis of cohort studies. Rheumatology 2009; 48 (10); 1309 -1313.
  3. Попкова Т. В., Новикова Д. С., Насонов Е. Л. Атеросклероз при ревматических заболеваниях. В кн.: Ревматология: Клинические рекомендации. М.; Гэотар-Медиа; 2010. 678-702.
  4. Peters M. J., Symmons D. P., McCarey D. W. et al. EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other types of inflammatory arthritis - TASK FORCE "Cardiovascular risk management in RA". Ann. Rheum. Dis. 2010; 69 (2); 325-331.
  5. van Halm V. P., Peters V. P., Voskuyl M. J. et al. Rheumatoid arthritis versus type 2 diabetes as a risk factor for cardiovascular disease: a cross-sectional study. Ann. Rheum. Dis. 2009; 68: 1395-1400.
  6. Российские рекомендации по диагностике и лечению артериальной гипертензии. В кн.: Оганов Р. Г. (ред.). Национальные клинические рекомендации: Сборник. 2-е изд. М.: Силицея-Полиграф; 2009. 292-332.
  7. Panoulas V. F., Douglas K. M. J., Milionis H. J. et al. Prevalence and associations of hypertension and its control in patients with rheumatoid arthritis. Rheumatology 2007; 46: 1477-1482.
  8. Panoulas V. F., Metsios G. S., Pace A. V. et al. Hypertension in rheumatoid arthritis. Rheumatology 2008;1 47: 1286-1298.
  9. Naranjo A., Sokka Т., Descalzo M. A. et аl. QUEST-RA Group. Cardiovascular disease in patients with rheumatoid arthritis: results from the QUEST-RA study. Arthr. Res. Ther. 2008; 10 (2): 30.
  10. Попкова Т. В., Новикова Д. С., Писарев В. В. и др. Факторы риска кардиоваскулярных заболеваний при ревматоидном артрите. Hayч.-практ. ревматол. 2009; 3: 4-11.
  11. Наn С., Robinson D. W., Hackett M. V. et al. Cardiovascular disease and risk factors in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. J. Rheumatol. 2006; 33: 2167-2172.
  12. Никитина Н. М., Ребров А. П. Артериальная гипертония у больных ревматоидным артритом. Рациональная фармакотерапия в кардиологии. 2009; 3: 67-70.
  13. Аршин Е. В. Эпидемиология артериальной гипертензии у больных ревматоидным артритом. Науч.-практ. ревматол. 2005; 5: 23-26.
  14. Оганов Р. Г., Масленникова Г. Я. Сердечно-сосудистые заболевания в Российской Федерации во второй половине ХХ столетия: тенденции, возможные причины, перспективы. Кардиология 2000; 6: 4-9.
  15. Лазебник Л. Б., Комиссаренко И. А., Милюкова О. М. Систолическая артериальная гипертония у пожилых: Рос. мед. журн. 1997; 5 (20): 28-36.
  16. Jórgensen K. T., Pedersen B. V., Jacobsen S. et al. National cohort study of reproductive risk factors for rheumatoid arthritis in Denmark: a role for hyperemesis, gestational hypertension and pre-eclampsia? Ann. Rheum. Dis. 2010; 69 (2): 358-363.
  17. Rodriguez L. A., Tolosa L. B., Ruigómez A. Rheumatoid arthritis in UK primary care: incidence and prior morbidity. Scand. J. Rheumatol. 2009; 38 (3); 173-177.
  18. Savoia C., Schiffrin E. L. Inflammation in hypertension. Curr. Opin. Nephrol. Hypertens. 2006; 15 (2): 152-158.
  19. Savoia C., Schiffrin E. L. Vascular inflammation in hypertension and diabetes: molecular mechanisms and therapeutic interventions. Clin. Sci. 2007; 112: 375-384.
  20. Bautista L. E., Vera L. M., Arenas I. A. et al. Independent association between inflammatory markers (C-reactive protein, interleukin-6 and TNF-alpha) and essential hypertension. J. Hum. Hypertens. 2005; 19: 149-154.
  21. Ощепкова Е. В., Дмитриев В. А., Титов В. Н. и др. Показатели неспецифического воспаления у больных гипертонической болезнью. Тер. арх. 2007; 12: 18-25.
  22. Kim К., Lee J. H., Chang H. J. et al. Association between blood pressure variability and inflammatory marker in hypertensive patients. Circ. J. 2008; 72: 293-298.
  23. Stumpf C., Jukic J., Yilmaz A. et al. Elevated VEGF-plasma levels in young patients with mild essential hypertension. Eur. J. Clin. Invest. 2009; 39 (1): 31-36.
  24. Chrysohoou C., Pitsavos C., Panagiotakos D. B. et al. Association between prehypertension status and inflammatory markers related to atherosclerotic disease: The ATTICA Study. Am. J. Hypertens. 2004; 17: 568-573.
  25. Sesso H., Buring J., Rifai N. et al. C-reactive protein and the risk of developing hypertension. J. A. M. A. 2003; 290 (22): 2945-2951.
  26. Pitsavos C., Chrysohoou C., Panagiotakos D. B. et al. Abdominal obesity and inflammation predicts hypertension among prehypertensive men and women: the ATTICA Study. Heart Vessels 2008; 23 (2): 96-103.
  27. Новикова Д. С., Попкова T. В., Мач Э. С., Насонов Е. Л. Ригидность артерии - интегральный показатель сердечно-сосудистого риска у больных ревматоидным артритом. Науч.-практ. ревматол. 2009, 5: 38-48.
  28. Montecucco F., Mach F. Common inflammatory mediators orchestrate pathophysiological processes in rheumatoid arthritis and atherosclerosis. Rheumatology 2009; 48: 11-22.
  29. Goodson N. J., Symmons D. P., Scott D. G. et al. Baseline levels of C-reactive protein and prediction of death from cardiovascular disease in patients with inflammatory polyarthritis: a ten-year followup of primary care-based inception cohort. Arthr. and Rheum. 2005; 52: 2293-2299.
  30. Poole C. D., Conway P., Currie C. J. An evaluation of the association between C-reactive protein, the change in C-reactive protein over one year, and all-cause mortality in chronic immune-mediated inflammatory disease managed in UK general practice. Rheumatology 2009; 48: 78-82.
  31. Savoia C., Schiffrin E. L. Reduction of C-reactive protein and the use of antihypertensive. Vasc. Hlth Risk Manage. 2007; 3 (6): 975-983.
  32. Oparil S., Zaman A. M., Calhoun D. A. Pathogenesis of hypertension. Ann. Intern. Med. 2003; 139: 761-766.
  33. Hall F. C., Dalbeth N. Disease modification and cardiovascular risk reduction: two sides of the same coin. Rheumatology 2005; 44: 1473-1482.
  34. Gasparyan A. Y., Stavropoulos-Kalinoglou A., Toms Т. Е. et al. Association of mean platelet volume with hypertension in rheumatoid arthritis. Inflamm. Allergy Drug Targets 2010; 9 (1): 45-50.
  35. Guzik T. J., Hoch N. E., Brown K. A. et al. Role of the Т cell in the genesis of angiotensin II - induced hypertension and vascular dysfunction. J. Exp. Med. 2007; 204: 2449-2460.
  36. Tomasson G., Aspelund Т., Jonsson T. et al. The effect of rheumatoid factor on mortality and coronary heart diseased. Ann. Rheum. Dis. 2010; 69 (9): 1649-1654.
  37. Goodson N. I., Willes N. J., Lunt N. C. Mortality on early inflammatory arthritis: cardiovascular mortality in seropositive patients. Arthr. and Rheum. 2002; 46: 2010-2019.
  38. Новикова Д. С., Попкова Т. В., Александрова Е. Н. и др. Роль антител к циклическому цитруллинированному пептиду (АЦЦП) и модифицированному цитруллинированному виментину (АМЦВ) в развитии атеросклеротического поражения сосудов при ревматоидном артрите. В кн.: Сборник материалов V съезда ревматологов России. М.; 2009. 57.
  39. Gerli R., Bartoloni Bocci E., Sherer Y. et al. Association of anti-cyclic citrullinated peptide antibodies with subclinical atherosclerosis in patients with rheumatoid arthritis. Ann. Rheum Dis. 2008; 67: 724-725.
  40. López-Longo F. J., Oliver-Minarro D., de la Torre I. et al. Association between anti-cyclic citrullinated peptide antibodies and ischemic heart disease in patients with rheumatoid arthritis. Arthr. and Rheum. 2009; 61: 419-424.
  41. Giles J. T., Malayeri A. A., Fernandes V. et al. Left ventricular structure and function in patients with rheumatoid arthritis, as assessed by cardiac magnetic resonance imaging. Arthr. and Rheum. 2010; 62 (4): 940-951.
  42. Elencov I. J., Wilder R. L., Chroussos G. P. et al. The sympatheticnerve - an integrative interface between two supersystems: the brain and the immune system. Pharmacol. Rev. 2000; 52: 595-638.
  43. Thayer J. F. Vagal tone and the inflammatory reflex. Cliv. Clin. J. Med. 2009; 76 (2): 23-26.
  44. Holman A. J., Ng E. Heart rate variability predicts anti-tumor necrosis factor therapy response for inflammatory arthritis. Auton. Neurosci. 2008; 143 (1-2): 58-67.
  45. Новикова Д. С., Попкова Т. В., Лисицина Т. А., Насонов Е. Л. Перспективы определения вариабельности ритма сердца при ревматоидном артрите и системной красной волчанке. Вестн. РАМН 2010; 9: 23-34.
  46. Fagard R. H., Stolarz К., Kuznetsova T. et al. Sympathetic activity, assessed by power spectral analysis of heart rate variability, in white-coat, masked and sustained hypertension versus true normotension. J. Hypertens. 2007; 25 (11): 2280-2285.
  47. Новикова Д. С., Попкова Т. В., Маркелова Е. И. и др. Клиническое значение оценки вариабельности ритма сердца у больных ревматоидным артритом. Клин. мед. 2009; 1: 27- 32.
  48. Дмитриев В. А., Ощепкова Е. В., Титов В. Н. и др. С-реактивный белок и интерлейкин-6 при поражении органов-мишеней на ранних стадиях у больных гипертонической болезнью. Кардиол. вестн. 2007; 2: 55-61.
  49. Panoulas V. F., Toms Т. Е., Metsios G. S. Target organ damage in patients with rheumatoid arthritis: the role of blood pressure and heart rate. Atherosclerosis 2010; 209 (1): 255-260.
  50. Попкова Т. В., Хелковская А. Н., Мач Э. С. и др. Сердечно-сосудистые заболевания при ревматоидном артрите. Тер. арх. 2007; 5: 9-14.
  51. Chung С. P., Oeser A., Joseph F. Prevalence of the metabolic syndrome is increased in rheumatoid arthritis and is associated with coronary atherosclerosis. Atherosclerosis 2008; 196 (2): 756-763.
  52. Попкова Т. В., Новикова Д. С., Насонов Е. Л. Кардиоваскулярные факторы риска при ревматических заболеваниях: связь с воспалением. Consilium Medicum. 2010; 2: 112- 118.
  53. Sidiropoulos P. I., Karvounaris S. A., Boumpas D. T. Metabolic syndrome in rheumatic disease: epidemiology, pathophysiology, and clinical implications. Arthr. Res. Ther. 2008; 10 (3): 207.
  54. Елисеев М. С., Барскова В. Г., Ильиных Е. В., Насонова В. А. Синдром инсулинорезистентности и подагра: исторический аспект и современное состояние проблемы. Клин. геронтол. 2005; 11 (4): 30-41.
  55. Panoulas V. F., Milionis H. J., Douglas K. M. et al. Association of serum uric acid with cardiovascular disease in rheumatoid arthritis. Rheumatology 2007; 46 (9): 1466-1470.
  56. Panoulas V. F., Douglas K. M., Smith J. P. et al. Transforming growth factor-betal 869T/C, but not interleukin-6 -174G/C, polymorphism associates with hypertension in rheumatoid arthritis. Rheumatology 2009; 48 (2): 113-118.
  57. Panoulas V. F., Douglas K. M., Smith J. P. et al. Galectin-2 (LGALS2) 3279C/T polymorphism may be independently associated with diastolic blood pressure in patients with rheumatoid arthritis. Clin. Exp. Hypertens. 2009; 31(2): 93-104.
  58. Каратеев А. Е., Яхно Н. Н., Лазебник Л. Б. Применение нестероидных противовоспалительных препаратов: Клинические рекомендации. М. : ИМА-ПРЕСС; 2009.
  59. Morrison A., Ramey D. R., van Adelsberg J., Watson D. J. Systematic review of trials of the effect of continued use of oral non-selective NSAIDs on blood pressure and hypertension. Curr. Med. Res. Opin. 2007; 23: 2395-2404.
  60. Мареев В. Ю., Агеев Ф. Т., Арутюнов Г. П. и др. Применение диклофенака и целебрекса у пациентов с артериальной гипертонией, остеоартрозом и болями в нижней части спины на фоне гипотензивной терапии аккупро или норваском (исследование ДОЦЕНТ). Сердеч. недостат. 2005; 6: 204-208.
  61. Burmester G., Lanas A., Biasucci L. The appropriate use of non-steroidal anti-inflammatory drugs in rheumatic disease: opinions of a multidisciplinary European expert panel. Ann. Rheum. Dis. 2010; 69 (10): 1738-1743.
  62. Solomon D. H., Avorn J., Katz J. N. Immunosuppressive medications hospitalization for cardiovascular events in patients with rheumatoid arthritis. Arthr. and Rheum. 2006; 54: 3790- 3800.
  63. Scott D. L., Smolen J. S., Kalden J. R. et al. Treatment of active rheumatoid arthritis with leflunomide: two year follow up of a double blind, placebo controlled trial versus sulfasalazine. Ann. Rheum. Dis. 2001; 60: 913-923.
  64. Rozman В., Praprotnik S., Logar D. et al. Leflunomide and hypertension. Ann. Rheum. Dis. 2002; 61: 567-569.
  65. Fox R. I., Herrmann M. L., Frangou C. G. et al. Mechanism of action for leflunomide in rheumatoid arthritis. Clin. Immunol. 1999; 93: 198-208.
  66. Li E. K., Tarn L. S., Tomlinson B. Leflunomide in the treatment of rheumatoid arthritis. Clin. Ther. 2004; 26: 447-459.
  67. Robert N., Wong G. W., Wright J. M. Effect of cyclosporine on blood pressure. Cochrane Database Syst. Rev. 2010; 20 (1): CD007893.
  68. Taler S. J., Textor S. C., Canzanello V. J., Schwartz L. Cyclosporin-induced hypertension: incidence, pathogenesis and management. Drug Saf. 1999; 20: 437-449.
  69. Schrama Y. C., Koomans H. A. Interactions of cyclosporin A and amlodipine: blood cyclosporin A levels, hypertension and kidney function. J. Hypertens. 1998; 16: 33-38.
  70. Wasco M. C., Hubert H., Lingala B. All-cause mortality in RA. Arthr. and Rheum. 2009, 58 (Suppl. 9): 276.
  71. Munro R., Morrison E., McDonald A. G. et al. Effect of disease modifying agents on the lipid profiles of patients with rheumatoid arthritis. Ann. Rheum. Dis. 1997; 56: 374 -377.
  72. Rho Y. H., Oeser A., Chung C. P. et al. Drugs used in the treatment of rheumatoid arthritis: relationship between current use and cardiovascular risk factors. Arch. Drug Inf. 2009; 2 (2): 34-40.
  73. Barnabe С., Martin B. J., Ghali W. A. Systematic review and meta-analysis: Anti-tumor necrosis factor alpha therapy and cardiovascular events in rheumatoid arthritis. Arthr. Care Res. 2010; 10: 1724-1732.
  74. Новикова Д. С., Попкова Т. В., Насонов Е. Л. Профилактика сердечно-сосудистых заболеваний при ревматоидном артрите. Тер. apx. 2009; 5: 88-96.
  75. Di Micco P., Ferrazzi P., Libré L. et al. Intima-media thickness evolution after treatment with infliximab in patients with rheumatoid arthritis. Int. J. Gen. Med., 2009; 30 (2): 141-144.
  76. Wasserman M. J., Weber D. A., Guthrie J. A. Infusion-related reactions to infliximab in patients with rheumatoid arthritis in a clinical practice setting: relationship to dose, antihistamine pretreatment, and infusion number. J. Rheumatol. 2004; 31 (10) 1912-1917.
  77. Lequerré Т., Vittecoq O., Klemmer N. Management of infusion reactions to infliximab in patients with rheumatoid arthritis or spondyloarthritis: experience from an immunotherapy unit of rheumatology. J. Rheumatol. 2006. 33 (7): 1307-1314.
  78. Wei L., MacDonald T. M., Walker B. R. Taking glucocorticoids by prescription is associated with subsequent cardiovascular disease. Ann. Intern. Med. 2004; 114: 764-770.
  79. Wolfe F., Michaud K. The risk of myocardial infarction and pharmacologic and nonpharmacologic myocardial infarction predictors in rheumatoid arthritis. A cohort and nested case-control analysis. Arthr. and Rheum. 2008; 58 (9): 2612-2621.
  80. Toms Т. Е., Panoulas V. F., Douglas K. M. et al. Statin use in rheumatoid arthritis in relation to actual cardiovascular risk: evidence for substantial under treatment of lipid associated cardiovascular risk? Ann. Rheum. Dis. 2010; 69 (4): 683-688.
  81. Stavropoulos-Kalinoglou A., Metsios G. S., Koutedakis Y. et al. Redefining overweight and obesity in rheumatoid arthritis patients. Ann. Rheum. Dis. 2007; 66: 1316-1321.
  82. Napoli M. D., Papa F. Angiotensin-converting enzyme inhibitor use is associated with reduced plasma concentration of C-reactive protein in patients with first-ever ischemic stroke. Stroke 2003; 34: 2922-2929.
  83. Sanz-Rosa D., Oubina M. P., Cediel E. et al. Effect of AT1receptor antagonism on vascular and circulating inflammatory mediators in SHR: role of NF-kappaB/IkappaB system. Am. J. Physiol. 2005; 288: 111-115.
  84. Fliser D., Buchholz K., Haller H. Antiinflammatory effects of angiotensin, II subtype 1 receptor blockade in hypertensive patients with microinflammation. Circulation 2004; 110: 1103- 1107.
  85. Dandona P., Dhindsa S., Ghanim H. et al. Angiotensin II and inflammation: the effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockade. J. Hum. Hypertens. 2007; 21: 20-27.
  86. Flammer A. J., Sudano I., Hermann F. et al. Angiotensin-converting enzyme inhibition improves vascular function in rheumatoid arthritis Circulation 2008; 117: 2262-2269.
  87. Беленков Ю. Н., Оганов Р. Г. (ред.). Кардиология: Нац. руководство. М.: Гэотар-Медиа; 2007.
  88. Yoshii Т., Iwai M., Li Z. et al. Regression of atherosclerosis by amlodipine via anti-inflammatory and anti-oxidative stress actions. Hvpertens. Res. 2006; 29 (6): 457-466.
  89. Shurtz-Swirski R., Farah R., Sela S. et al. The effect of calcium channel blocker lercanidipine on lowgrade inflammation parameters in essential hypertension patients. Harefuah 2006; 45 (12): 895-899.
  90. Yao R., Cheng X., Liao Y. H. et al. Molecular mechanisms of felodipine suppressing atherosclerosis in high-cholesterol-diet apolipoprotein E-knockout mice. J. Cardiovasc. Pharmacol 2008; 51 (2): 188-195.
  91. Cohen J. D. Overview of physiology, vascular biology and mechanisms of hypertension. J. Manag. Care Pharm. 2007; 13 (5): 6-8.
  92. Bakris G. L. Pharmacological augmentation of endothelium-derived nitric oxide synthesis. J. Manag. Care Pharm. 2007; 13(5): 9-12.
  93. Ситникова М. Ю., Иванов С. Г., Хмельницкая К. А. Плейотропные эффекты β-адреноблокаторов в терапии сердечно-сосудистых заболеваний: влияние на перекисное окисление липидов, свойства эндотелия и эволюцию атеросклероза. Кардиология 2009; 6: 61-66.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2011 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
 

Address of the Editorial Office:

  • Novij Zykovskij proezd, 3, 40, Moscow, 125167

Correspondence address:

  • Alabyan Street, 13/1, Moscow, 127055, Russian Federation

Managing Editor:

  • Tel.: +7 (926) 905-41-26
  • E-mail: e.gorbacheva@ter-arkhiv.ru

 

 © 2018-2021 "Consilium Medicum" Publishing house


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies